PCM
IRWD icon

Peregrine Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Peregrine Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,023,882
Closed -$11.7M – 351
2020
Q4 		$11.7M Sell
1,023,882
-93,149
-8% -$1.02M 0.22% 211
2020
Q3 		$10M Sell
1,117,031
-106,247
-9% -$1.06M 0.27% 133
2020
Q2 		$12.6M Sell
1,223,278
-41,039
-3% -$420K 0.36% 114
2020
Q1 		$12.8M Buy
1,264,317
+4,370
+0.3% +$51.4K 0.46% 89
2019
Q4 		$16.8M Sell
1,259,947
-14,743
-1% -$163K 0.43% 107
2019
Q3 		$10.9M Buy
1,274,690
+41,908
+3% +$407K 0.3% 134
2019
Q2 		$13.5M Buy
+1,232,782
New +$13.8M 0.33% 129

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Peregrine Capital Management's IRWD Position: Q1 2021 in Review

Peregrine Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2021, closing a stake of 1,023,882 shares — an estimated $11.7M sold.

Peregrine Capital Management first reported a position in IRWD in Q2 2019 and held it in 7 quarters. The position peaked at $16.8M in Q4 2019. 209 funds tracked by Wall St. Rank hold IRWD as of Q1 2021.

  • Peregrine Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 1,023,882 Ironwood Pharmaceuticals shares in Q1 2021, an estimated $11.7M.
  • Peregrine Capital Management first reported a position in Ironwood Pharmaceuticals in Q2 2019 and held it in 7 quarters.
  • Peregrine Capital Management's Ironwood Pharmaceuticals position peaked at $16.8M in Q4 2019.
  • 209 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2021.

Based on Peregrine Capital Management's 13F filing for Q1 2021, filed 11 May 2021.